Regent Investment Management LLC raised its stake in Becton Dickinson and Co (NYSE:BDX) by 5.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,337 shares of the medical instruments supplier’s stock after buying an additional 175 shares during the quarter. Regent Investment Management LLC’s holdings in Becton Dickinson and were worth $833,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. CWM LLC lifted its position in shares of Becton Dickinson and by 5.6% during the fourth quarter. CWM LLC now owns 830 shares of the medical instruments supplier’s stock worth $187,000 after purchasing an additional 44 shares in the last quarter. Mitchell Mcleod Pugh & Williams Inc. lifted its position in shares of Becton Dickinson and by 1.2% during the fourth quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 4,123 shares of the medical instruments supplier’s stock worth $929,000 after purchasing an additional 47 shares in the last quarter. Abner Herrman & Brock LLC lifted its position in shares of Becton Dickinson and by 4.5% during the fourth quarter. Abner Herrman & Brock LLC now owns 1,105 shares of the medical instruments supplier’s stock worth $249,000 after purchasing an additional 48 shares in the last quarter. Providence Capital Advisors LLC lifted its position in shares of Becton Dickinson and by 0.5% during the fourth quarter. Providence Capital Advisors LLC now owns 10,240 shares of the medical instruments supplier’s stock worth $2,307,000 after purchasing an additional 48 shares in the last quarter. Finally, Cigna Investments Inc. New lifted its position in shares of Becton Dickinson and by 0.6% during the fourth quarter. Cigna Investments Inc. New now owns 7,891 shares of the medical instruments supplier’s stock worth $1,778,000 after purchasing an additional 48 shares in the last quarter. 84.87% of the stock is currently owned by institutional investors.

Several analysts have recently issued reports on the stock. TheStreet raised shares of Becton Dickinson and from a “c+” rating to an “a” rating in a research report on Tuesday, February 5th. Piper Jaffray Companies increased their price target on shares of Becton Dickinson and to $274.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 5th. Zacks Investment Research raised shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $243.00 price target on the stock in a research report on Tuesday, January 8th. ValuEngine cut shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Monday, April 1st. Finally, Morgan Stanley reduced their price target on shares of Becton Dickinson and from $265.00 to $240.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 2nd. One research analyst has rated the stock with a sell rating, five have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Becton Dickinson and presently has an average rating of “Buy” and an average price target of $256.25.

In other Becton Dickinson and news, CEO Vincent A. Forlenza sold 11,340 shares of the stock in a transaction that occurred on Monday, February 25th. The shares were sold at an average price of $250.40, for a total value of $2,839,536.00. Following the transaction, the chief executive officer now directly owns 227,250 shares in the company, valued at $56,903,400. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Vincent A. Forlenza sold 8,309 shares of the stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $255.13, for a total transaction of $2,119,875.17. Following the completion of the transaction, the chief executive officer now owns 222,785 shares in the company, valued at $56,839,137.05. The disclosure for this sale can be found here. Insiders have sold 29,684 shares of company stock worth $7,518,574 over the last 90 days. Insiders own 0.12% of the company’s stock.

Shares of BDX stock traded down $2.47 during trading hours on Monday, reaching $225.42. 15,613 shares of the stock were exchanged, compared to its average volume of 1,444,794. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.62 and a current ratio of 0.97. Becton Dickinson and Co has a 12-month low of $208.62 and a 12-month high of $265.87. The firm has a market capitalization of $61.32 billion, a price-to-earnings ratio of 20.45, a PEG ratio of 1.57 and a beta of 1.21.

Becton Dickinson and (NYSE:BDX) last released its earnings results on Tuesday, February 5th. The medical instruments supplier reported $2.70 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.58 by $0.12. Becton Dickinson and had a net margin of 5.69% and a return on equity of 14.65%. The firm had revenue of $4.16 billion for the quarter, compared to analyst estimates of $4.10 billion. During the same period in the prior year, the firm earned $2.48 earnings per share. The business’s quarterly revenue was up 35.1% compared to the same quarter last year. Equities analysts forecast that Becton Dickinson and Co will post 12.08 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, March 29th. Investors of record on Friday, March 8th were paid a dividend of $0.77 per share. The ex-dividend date was Thursday, March 7th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.37%. Becton Dickinson and’s payout ratio is 27.97%.

TRADEMARK VIOLATION WARNING: “Becton Dickinson and Co (BDX) Holdings Lifted by Regent Investment Management LLC” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.watchlistnews.com/becton-dickinson-and-co-bdx-holdings-lifted-by-regent-investment-management-llc/2981306.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Story: FAANG Stocks

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.